KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenon Pharmaceuticals (XENE) Debt to Equity: 2017-2020

Historic Debt to Equity for Xenon Pharmaceuticals (XENE) over the last 2 years, with Mar 2020 value amounting to $0.08.

  • Xenon Pharmaceuticals' Debt to Equity fell 49.15% to $0.08 in Q1 2020 from the same period last year, while for Mar 2020 it was $0.08, marking a year-over-year decrease of 49.15%. This contributed to the annual value of $0.17 for FY2019, which is N/A change from last year.
  • According to the latest figures from Q1 2020, Xenon Pharmaceuticals' Debt to Equity is $0.08, which was down 50.64% from $0.17 recorded in Q4 2019.
  • Xenon Pharmaceuticals' 5-year Debt to Equity high stood at $0.24 for Q1 2018, and its period low was $0.08 during Q1 2020.
  • Its 3-year average for Debt to Equity is $0.18, with a median of $0.18 in 2019.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Debt to Equity skyrocketed by 54.24% in 2019 and then plummeted by 49.15% in 2020.
  • Xenon Pharmaceuticals' Debt to Equity (Quarterly) stood at $0.19 in 2017, then reached $0.13 in 2018, then skyrocketed by 54.24% to $0.17 in 2019, then slumped by 49.15% to $0.08 in 2020.
  • Its Debt to Equity stands at $0.08 for Q1 2020, versus $0.17 for Q4 2019 and $0.21 for Q3 2019.